HPV Type-specific Risks of High-grade CIN During 4 Years of Follow-up: a Population-based Prospective Study

Overview

Journal Br J Cancer

Specialty Oncology

Date 2007 Jun 7

PMID 17551490

Citations 30

Authors

P Naucler

W Ryd

S Tornberg

A Strand

G Wadell

B G Hansson

E Rylander

J Dillner

Affiliations

Soon will be listed here.

Abstract

We followed a population-based cohort of 5696 women, 32-38 years of age, by registry linkage with cytology and pathology registries during a mean follow-up time of 4.1 years to assess the importance for CIN2+ development of type-specific HPV DNA positivity at baseline. HPV 16, 31 and 33 conveyed the highest risks and were responsible for 33.1, 18.3 and 7.7% of CIN2+ cases, respectively. Women infected with HPV 18, 35, 39, 45, 51, 52, 56, 58, 59 and 66 had significantly lower risks of CIN2+ than women infected with HPV 16. After adjustment for infection with other HPV types, HPV types 35, 45, 59 and 66 had no detectable association with CIN2+. In summary, the different HPV types found in cervical cancer show distinctly different CIN2+ risks, with high risks being restricted to HPV 16 and its close relatives HPV 31 and HPV 33.

Citing Articles

Risk of cervical high-grade squamous intraepithelial neoplasia in cytologic negative and persistently high-risk human papillomavirus positive patients according to genotypes: a retrospective single center analysis.

Kipp B, Ulrich E, van Meegen C, Schwenzer T BMC Infect Dis. 2024; 24(1):558.

PMID: 38834951 PMC: 11151640. DOI: 10.1186/s12879-024-09449-z.

High prevalence of HPV16 and high-grade cytology in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2.

Damgaard R, Jenkins D, Stoler M, van de Sandt M, Lycke K, de Koning M Acta Obstet Gynecol Scand. 2023; 102(9):1227-1235.

PMID: 37469102 PMC: 10407017. DOI: 10.1111/aogs.14627.

Risk of Intraepithelial Neoplasia Grade 3 or Worse (CIN3+) among Women Examined by a 5-Type HPV mRNA Test during 2003 and 2004, Followed through 2015.

Rad A, Sorbye S, Tiwari S, Lochen M, Skjeldestad F Cancers (Basel). 2023; 15(12).

PMID: 37370716 PMC: 10296297. DOI: 10.3390/cancers15123106.

Prevalence of higher-grade dysplasia in persistently high-risk human papillomavirus positive, cytology negative women after introduction of the new cervical cancer screening in Germany.

Berger L, Wolf-Breitinger M, Weiss C, Tuschy B, Berlit S, Sutterlin M Cancer Causes Control. 2023; 34(5):469-477.

PMID: 36854989 PMC: 10105660. DOI: 10.1007/s10552-023-01677-z.

The efficacy of human papillomavirus vaccination in young Japanese girls: the interim results of the OCEAN study.

Hiramatsu K, Ueda Y, Yagi A, Morimoto A, Egawa-Takata T, Nakagawa S Hum Vaccin Immunother. 2021; 18(1):1951098.

PMID: 34802371 PMC: 8920229. DOI: 10.1080/21645515.2021.1951098.

References

Schiffman M, Kjaer S . Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003; (31):14-9. DOI: 10.1093/oxfordjournals.jncimonographs.a003476. View

Berkhof J, Bulkmans N, Bleeker M, Bulk S, Snijders P, Voorhorst F . Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev. 2006; 15(7):1268-73. DOI: 10.1158/1055-9965.EPI-05-0764. View

Peto J, Gilham C, Deacon J, Taylor C, Evans C, BINNS W . Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer. 2004; 91(5):942-53. PMC: 2409880. DOI: 10.1038/sj.bjc.6602049. View

Miettinen O . Proportion of disease caused or prevented by a given exposure, trait or intervention. Am J Epidemiol. 1974; 99(5):325-32. DOI: 10.1093/oxfordjournals.aje.a121617. View

Koutsky L, Holmes K, Critchlow C, Stevens C, Paavonen J, Beckmann A . A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992; 327(18):1272-8. DOI: 10.1056/NEJM199210293271804. View

Bosch F, Manos M, Munoz N, Sherman M, Jansen A, Peto J . Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87(11):796-802. DOI: 10.1093/jnci/87.11.796. View

de Roda Husman A, Walboomers J, Hopman E, Bleker O, Helmerhorst T, Rozendaal L . HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: the age-related pattern. J Med Virol. 1995; 46(2):97-102. DOI: 10.1002/jmv.1890460203. View

Jacobs M, Snijders P, van den Brule A, Helmerhorst T, Meijer C, Walboomers J . A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol. 1997; 35(3):791-5. PMC: 229677. DOI: 10.1128/jcm.35.3.791-795.1997. View

Liaw K, Glass A, Manos M, Greer C, Scott D, Sherman M . Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst. 1999; 91(11):954-60. DOI: 10.1093/jnci/91.11.954. View

10.

Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, Shah K . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1):12-9. DOI: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. View

11.

Winer R, Kiviat N, Hughes J, Adam D, Lee S, Kuypers J . Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005; 191(5):731-8. DOI: 10.1086/427557. View

12.

Schiffman M, Herrero R, DeSalle R, Hildesheim A, Wacholder S, Rodriguez A . The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005; 337(1):76-84. DOI: 10.1016/j.virol.2005.04.002. View

13.

Khan M, Castle P, Lorincz A, Wacholder S, Sherman M, Scott D . The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005; 97(14):1072-9. DOI: 10.1093/jnci/dji187. View

14.

Belinson J, Qiao Y, Pretorius R, Zhang W, Elson P, Li L . Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001; 83(2):439-44. DOI: 10.1006/gyno.2001.6370. View

15.

Forslund O, Antonsson A, Edlund K, van den Brule A, Hansson B, Meijer C . Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol. 2002; 66(4):535-41. DOI: 10.1002/jmv.2178. View

16.

Bosch F, Lorincz A, Munoz N, Meijer C, Shah K . The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55(4):244-65. PMC: 1769629. DOI: 10.1136/jcp.55.4.244. View

17.

Sherman M, Lorincz A, Scott D, Wacholder S, Castle P, Glass A . Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003; 95(1):46-52. DOI: 10.1093/jnci/95.1.46. View

18.

Clifford G, Smith J, Plummer M, Munoz N, Franceschi S . Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003; 88(1):63-73. PMC: 2376782. DOI: 10.1038/sj.bjc.6600688. View

19.

Munoz N, Bosch F, de Sanjose S, Herrero R, Castellsague X, Shah K . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-27. DOI: 10.1056/NEJMoa021641. View

20.

Elfgren K, Rylander E, Radberg T, Strander B, Strand A, Paajanen K . Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol. 2005; 193(3 Pt 1):650-7. DOI: 10.1016/j.ajog.2005.01.056. View